As a top 10 pharma company prepared for the launch of a new hematology drug, they lacked a deep understanding of non-clinical factors that impact their patients’ journeys and access to therapy.
In this case study you’ll learn how they partnered with Clarify Health to use an integrated approach to traditional and non-traditional data and analyses to guide their product launch and access planning. Download the case study to learn how the brand team successfully addressed the following questions:
What are our patients’ income levels, and can they afford the out-of-pocket burden of the treatment?
Are our patients likely to be receptive to preventive care, based on their education levels?
How easy is it for our patients to access infusion centers of excellence (CoEs) for treatment?